Laura C Cappelli
Overview
Explore the profile of Laura C Cappelli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
1537
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cappelli L
Semin Arthritis Rheum
. 2024 Nov;
70S:152582.
PMID: 39578183
Immune checkpoint molecules like PD-1 and its ligand PD-L1 and CTLA-4 are important regulators of the immune system. Medications blocking these pathways, immune checkpoint inhibitors, have been used to treat...
2.
Kao C, Charmsaz S, Alden S, Brancati M, Li H, Balaji A, et al.
J Clin Invest
. 2024 Oct;
134(20).
PMID: 39403935
BACKGROUNDImmune-related adverse events (irAEs) and their associated morbidity/mortality are a key concern for patients receiving immune checkpoint inhibitors (ICIs). Prospective evaluation of the drivers of irAEs in a diverse pan-tumor...
3.
Buckley M, Balaji Warner A, Brahmer J, Cappelli L, Sharfman W, Fuchs E, et al.
Oncologist
. 2024 Jul;
30(1).
PMID: 39066587
Background: Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment but can trigger immune-related encephalitis. We report one of the largest case series of patients with immune-related encephalitis and review of...
4.
Wallwork R, Kotzin J, Cappelli L, Mecoli C, Bingham 3rd C, Wigley F, et al.
Semin Arthritis Rheum
. 2024 May;
67:152460.
PMID: 38733668
Objective: Immune checkpoint inhibitor (ICI) therapies have dramatically improved outcomes in multiple cancers. ICI's mechanism of action involves immune system activation to augment anti-tumor immunity. Patients with pre-existing autoimmune diseases,...
5.
Singh N, Shahane A, Sparks J, Bitoun S, Cappelli L
Rheum Dis Clin North Am
. 2024 Apr;
50(2):269-279.
PMID: 38670725
The introduction of immune checkpoint inhibitors (ICIs) has changed the landscape of the treatment of cancer. Several immune-related adverse events (irAEs) have now been described such as ICI-inflammatory arthritis (IA),...
6.
Chen S, Semenov Y, Alloo A, Bach D, Betof Warner A, Bougrine A, et al.
J Immunother Cancer
. 2024 Apr;
12(4).
PMID: 38599660
With an increasing number of patients eligible for immune checkpoint inhibitors, the incidence of immune-related adverse events (irAEs) is on the rise. Dermatologic immune-related adverse events (D-irAEs) are the most...
7.
Chen S, McMiller T, Soni A, Succaria F, Sidhom J, Cappelli L, et al.
J Transl Med
. 2024 Mar;
22(1):241.
PMID: 38443917
Background: Tumor regression following immune checkpoint blockade (ICB) is often associated with immune-related adverse events (irAEs), marked by inflammation in non-cancerous tissues. This study was undertaken to investigate the functional...
8.
Pappas D, OBrien J, Moore P, Dodge R, Germino R, Masri K, et al.
J Rheumatol
. 2024 Feb;
51(5):452-461.
PMID: 38359941
Objective: This real-world analysis assessed baseline demographics/characteristics and treatment patterns/effectiveness in patients with rheumatoid arthritis (RA) initiating tofacitinib (TOF) in the US CorEvitas RA Registry. Methods: The primary analysis of...
9.
Daetwyler E, Wallrabenstein T, Konig D, Cappelli L, Naidoo J, Zippelius A, et al.
J Immunother Cancer
. 2024 Jan;
12(1).
PMID: 38233099
Immune checkpoint inhibitor (ICI) treatment has become an important therapeutic option for various cancer types. Although the treatment is effective, ICI can overstimulate the patient's immune system, leading to potentially...
10.
Cappelli L, Hines D, Wang H, Bingham C, Darrah E
ACR Open Rheumatol
. 2023 Dec;
6(2):81-90.
PMID: 38058274
Background: Given that autoantibodies to peptidylarginine deiminase 4 (PAD4) are associated with erosive disease in established rheumatoid arthritis (RA), this study was conducted to compare the clinical and prognostic use...